DoH signs MoU with M42 and AbbVie. Credit: The Department of Health – Abu Dhabi/ PRNewswire.

The Department of Health Abu Dhabi (DoH) has signed a memorandum of understanding with integrated healthcare company M42 and AbbVie Biopharmaceuticals to advance personalised medicine and genomics in the city.

M42 was created through the combination of Mubadala Health and G42 Healthcare.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The collaboration aims to advance precision medicine for the diagnosis and treatment of non-small cell lung cancer (NSCLC) and multiple myeloma.

The DoH intends to advance research that will enable broad patient access to new approaches in healthcare, contributing to changes in policy and guideline implementation.

DoH Research and Innovation Center executive director Dr Asma Al Mannaei stated: “It is without a doubt that personalised medicine and genomics hold transformative potential to reshape the delivery of care and improve outcomes.

“Abu Dhabi continues to harness the power of these fields to unlock a new era of healthcare where every patient’s journey is guided by their own genetic blueprint, leading to enhanced quality of life and a brighter future for generations to come.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

With a focus on precision medicine tailored to the needs of individuals, the partnership aims to progress the unique genomics programme of the United Arab Emirates and convert scientific advancements into tangible patient benefits.

Last year, Abu Dhabi introduced the first personalised precision medicine programme for oncology in the region, as part of its preventive healthcare efforts.

This programme includes personalised, predictive and precision medicine leveraging genomics to transform drug therapy, diagnostics and prevention.

AbbVie Gulf and Levant general manager Hassan Sabbah stated: “This partnership aims to advance precision medicine in diagnosis and treatment to help enable broader patient access in the UAE to innovative therapies.

“Our efforts are progressing to launch several initiatives that support research and clinical trials and develop innovative solutions to deal effectively with local and regional health needs, challenges and burdens.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
NorthWest EHealth has won three 2025 Pharmaceutical Technology Excellence Awards for Innovation, Safety and Diversity. Explore how its ConneXon platform is transforming SAE reporting and real-time safety oversight, while FARSITE delivers socio-economically inclusive recruitment to boost trial efficiency, data integrity and regulatory-grade representativeness.

Discover the Impact